Barchart on MSN4h
How Is Gilead Sciences' Stock Performance Compared to Other Pharmaceutical Stocks?
Valued at a market cap of $143.8 billion, Gilead Sciences, Inc. (GILD) is a biopharmaceutical company that discovers, ...
Zacks Investment Research on MSN1d
Gilead Sciences, Inc. (GILD) Hits Fresh High: Is There Still Room to Run?
Shares have been on the move with the stock up 17.1% over the past month. The stock hit a new 52-week high of $117.39 in the previous session. Gilead Sciences has gained 24.2% since the start of the ...
Bank of America Securities Remains a Buy on Gilead Sciences (GILD)
In a report released today, Tim Anderson from Bank of America Securities maintained a Buy rating on Gilead Sciences (GILD – Research Report), ...
Wells Fargo Reaffirms Their Buy Rating on Gilead Sciences (GILD)
Wells Fargo analyst Mohit Bansal maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of $140.00.